Investors should monitor the upcoming Phase 3 trial initiation and expanded cohort data in 1H 2026, which could serve as major catalysts. The strong survival data and extended cash runway into 2029 reduce near-term dilution risk and support long-term value creation.
Price Chart
Executive Summary
Immuneering reported strong clinical data from its Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer, showing 64% 12-month overall survival—well above the 35% benchmark—while also reducing R&D expenses and improving cash position to $217 million with runway into 2029. The company is on track to initiate a pivotal Phase 3 trial (MAPKeeper 301) in mid-2026.
Key Financial Metrics
Key Facts
- 64% 12-month overall survival in first-line pancreatic cancer patients treated with atebimetinib + mGnP vs. 35% standard of care
- Cash, cash equivalents, and marketable securities totaled $217.0 million as of December 31, 2025, up from $36.1 million in 2024
- R&D expenses decreased to $42.0 million in 2025 from $48.0 million in 2024
- Net loss narrowed to $56.0 million in 2025 from $61.0 million in 2024
- Phase 3 MAPKeeper 301 trial expected to dose first patient in mid-2026, with FDA and EMA alignment secured
- Added to Nasdaq Biotechnology Index (NBI) in December 2025
Financial Impact
Reduced annual net loss by $5 million and increased cash position by $180.9 million year-over-year, driven by lower R&D spend and financing activities
Risk Factors
- Clinical trial results may not replicate in larger Phase 3 studies
- Regulatory delays or setbacks in trial execution could impact timeline
- Biotech sector volatility and reliance on future financing despite current runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250985 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $3.71 $3.83 | ▲ +3.23% | ▲ +2.67% | $3.83 (+3.23%) |
Oct 2, 2026 25d ago | Press Release | $4.07 $4.04 | ▼ −0.74% | ▼ −1.41% | $3.83 (−5.90%) |
Sep 28, 2026 29d ago | Press Release | $4.16 $4.13 | ▼ −0.72% | ▼ −0.54% | $3.83 (−7.93%) |
Aug 26, 2026 8w ago | Press Release | $5.21 $4.99 | ▼ −4.22% | ▼ −4.00% | $3.83 (−26.49%) |
Aug 5, 2026 11w ago | 8-K | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.83 (−12.76%) |
Aug 5, 2026 11w ago | Press Release | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.83 (−12.76%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.12 $4.19 | ▲ +1.70% | ▲ +1.16% | $3.83 (−7.04%) |
Jun 1, 2026 21w ago | 8-K | $4.28 $4.55 | ▲ +6.31% | ▲ +7.00% | $3.83 (−10.51%) |
May 15, 2026 23w ago | Press Release | $5.16 $4.87 | ▼ −5.62% | ▼ −5.56% | $3.83 (−25.78%) |
Apr 21, 2026 27w ago | Press Release | $5.89 $6.13 | ▲ +4.07% | ▲ +4.47% | $3.83 (−34.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers